US · ESPR
Esperion Therapeutics, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Ann Arbor, MI 48108
- Website
- esperion.com
Price · as of 2024-12-31
$3.11
Market cap 661.73M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $46.97 | +1,410.29% |
| Intrinsic Value(DCF) | $912.02 | +29,225.4% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $17.40 | $0.00 | $0.00 | ||
| 2014 | $74.39 | $52.53 | |||
| 2015 | $15.47 | ||||
| 2016 | $31.10 | ||||
| 2017 | $75.26 | ||||
| 2018 | $47.05 | $0.00 | $0.00 | ||
| 2019 | $50.46 | $48.57 | $0.00 | $0.00 | $38.08 |
| 2020 | $30.34 | $35.10 | $8.58 | $0.00 | $0.00 |
| 2021 | $4.74 | $8.64 | $0.00 | $0.00 | $508.54 |
| 2022 | $4.57 | $22.56 | $0.00 | $0.00 | $0.00 |
| 2023 | $2.19 | $27.28 | $0.00 | $0.00 | $0.00 |
| 2024 | $1.69 | $46.97 | $4,315.70 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Esperion Therapeutics, Inc.'s (ESPR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $46.97
- Current price
- $3.11
- AI upside
- +1,410.29%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$912.02
+29,225.4% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ESPR | Esperion Therapeutics, In… | $3.11 | 661.73M | +1,410% | +29,225% | — | — | -6.11 | -0.81 | 0.95 | 100.78 | — | -0.81 | 79.36% | 16.37% | -15.57% | 12.27% | 177.11% | -18.83% | -1.52 | 0.92 | 1.37 | 0.91 | 58.98 | -8621.00% | 18566.00% | -8231.00% | -7.58% | -0.10 | -78.04% | 0.00% | 0.00% | 3.87% | 14.02 | -31.82 | 2.30 | -4.45 |
| ABSI | Absci Corporation | $2.74 | 412.02M | +823% | -47% | — | +302% | -3.34 | 1.92 | 75.86 | -2.57 | — | 2.56 | -1277.57% | -2401.59% | -2274.06% | -58.04% | -127.20% | -47.86% | 0.06 | -192.72 | 4.67 | 3.92 | 0.33 | -2167.00% | -2071.00% | 1116.00% | -21.17% | -2.53 | -85.05% | 0.00% | 0.00% | 0.00% | -2.22 | -3.32 | 53.29 | 1.58 |
| AQST | Aquestive Therapeutics, I… | $4.00 | 397.23M | +466% | -73% | — | — | -5.21 | -3.82 | 3.99 | -7.37 | -1.78 | -3.82 | 68.95% | -53.46% | -76.68% | 52.97% | 32.25% | -55.57% | -0.63 | -1.83 | 4.68 | 4.18 | 1.26 | 29231.00% | 1380.00% | 38702.00% | -15.63% | -1.90 | 37.66% | 0.00% | 0.00% | 18.71% | -6.38 | -5.46 | 3.41 | -3.77 |
| CRVS | Corvus Pharmaceuticals, I… | $18.26 | 1.53B | — | — | — | — | -4.52 | 8.65 | — | -8.41 | -5.57 | 8.65 | 0.00% | — | — | -174.85% | 1026.95% | -108.85% | 0.03 | — | 1.54 | 1.47 | 0.28 | 8124.00% | — | 607.00% | -9.02% | -0.72 | 947.77% | 0.00% | 0.00% | 0.00% | -8.38 | -9.08 | — | -4.40 |
| EBS | Emergent BioSolutions Inc… | $8.15 | 434.81M | +481% | -56% | +80% | — | 9.14 | 0.92 | 0.65 | 3.56 | — | 5.59 | 48.62% | 13.47% | 7.08% | 10.46% | 6.53% | 3.88% | 1.09 | 1.69 | 5.01 | 2.19 | 1.54 | -12583.00% | -2881.00% | 33799.00% | 32.60% | 1.29 | 16.09% | 0.00% | 0.00% | 48.82% | 8.47 | 5.41 | 1.14 | 1.49 |
| OFIX | Orthofix Medical Inc. | $13.53 | 535.78M | +193% | -60% | — | — | — | 1.18 | 0.65 | -30.45 | — | 2.92 | 67.09% | -8.33% | -11.21% | 0.00% | -11.44% | 0.00% | 0.51 | -3.92 | 2.45 | 1.28 | -6.59 | -3091.00% | 285.00% | -8592.00% | -0.24% | 0.20 | -0.21% | 0.00% | — | 0.00% | -9.94 | -532.03 | 0.83 | 1.24 |
| OLMA | Olema Pharmaceuticals, In… | $24.20 | 1.9B | — | — | — | — | -2.09 | 0.66 | — | 1.14 | -74.60 | 0.66 | 0.00% | — | — | -39.07% | 974.77% | -35.57% | 0.00 | — | 10.50 | 10.45 | 0.97 | 280.00% | — | 2482.00% | -38.59% | -2.50 | 716.12% | 0.00% | 0.00% | 26.56% | 1.14 | 1.55 | — | 2.53 |
| RGNX | REGENXBIO Inc. | $9.04 | 457.63M | +97% | -72% | — | — | -1.38 | 1.21 | 3.77 | -0.81 | — | 1.21 | 59.72% | -280.03% | -272.54% | -79.49% | -200.49% | -43.68% | 0.32 | -18.43 | 2.69 | 2.48 | -0.12 | -2375.00% | -766.00% | -2312.00% | -55.93% | -1.68 | -150.84% | 0.00% | 0.00% | 10.02% | -0.69 | -0.92 | 1.93 | -2.91 |
| SIGA | SIGA Technologies, Inc. | $6.47 | 463.33M | +352% | -48% | — | -5% | 6.20 | 1.70 | 2.65 | 3.01 | — | 1.71 | 77.44% | 50.45% | 42.69% | 28.70% | 100.67% | 23.75% | 0.00 | — | 9.12 | 6.97 | -2.20 | -1263.00% | -86.00% | -4860.00% | 13.27% | 1.92 | 90.03% | 11.62% | 72.10% | 13.06% | 3.03 | 4.36 | 1.53 | 10.11 |
| SNDL | SNDL Inc. | $1.54 | 396.55M | +1,401% | +62% | -9% | — | -5.99 | 0.51 | 0.63 | -11.63 | — | 0.61 | 26.11% | -11.28% | -10.30% | -8.20% | -8.54% | -6.82% | 0.13 | -13.49 | 5.10 | 3.06 | 1.60 | -4162.00% | 126.00% | -27858.00% | 7.62% | 0.61 | 3.96% | 0.00% | 0.00% | 8.92% | -4.62 | 10.92 | 0.52 | 0.99 |
| VTYX | Ventyx Biosciences, Inc. | $13.97 | 1B | — | — | — | — | -0.76 | 0.40 | — | 0.71 | — | 0.40 | 0.00% | — | — | -54.27% | -573.99% | -48.76% | 0.04 | — | 17.97 | 17.09 | 0.11 | -4030.00% | — | -2151.00% | -128.50% | -10.24 | -506.96% | 0.00% | 0.00% | 0.00% | 0.70 | 0.80 | — | -0.92 |
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
- CEO
- Sheldon L. Koenig
- Employees
- 304
- Beta
- 1.11
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($912.02 ÷ $3.11) − 1 = +29,225.4% (DCF, example).